Description: Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Home Page: www.synairgen.com
Mailpoint 810
Southampton,
SO16 6YD
United Kingdom
Phone:
44 23 8051 2800
Officers
| Name | Title |
|---|---|
| Mr. Richard Marsden | CEO, MD & Exec. Director |
| Prof. Stephen T. Holgate CBE, M.D. | Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board |
| Mr. John Ward | CFO & Exec. Director |
| Dr. Phillip David Monk | Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director |
| Prof. Donna Davies | Co-Founder & Member of Scientific Advisory Board |
| Prof. Ratko Djukanovic | Co-Founder & Member of Scientific Advisory Board |
| Ms. Brooke S Clarke | Sr. VP & Head of Communications |
| Dr. Gareth E. Walters Ph.D. | Chief Regulatory Officer |
| Ms. Jody Brookes | Sr. VP & Head of Clinical Operations |
| Mr. Richard Hennings | Chief Commercial Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3872 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |